Actively Recruiting
Clinical Study of 68Ga-NYM207 PETCT Imaging to Detect Hepatocellular Carcinoma
Led by Peking Union Medical College Hospital · Updated on 2026-10-21
100
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety, tolerability, and diagnostic ability of a new imaging agent called 68Ga-NYM207 in people with hepatocellular carcinoma HCC, a type of liver cancer. This phase III study aims to understand how well 68Ga-NYM207 works as a non-invasive tool to detect HCC by using PETCT scans. Participants will receive a single intravenous dose of 68Ga-NYM207. For Phase A, PET scans are performed at 15, 30, 60, and 120 minutes after the injection to assess safety and imaging features. In Phase B, a dedicated whole-body PETCT scan will be done about 45 to 75 minutes after administration to evaluate the diagnostic performance of the agent. During the study, participants will be closely monitored for safety and tolerability up to one month after receiving 68Ga-NYM207. Imaging will be analyzed to measure lesion detection accuracy, including lesion uptake levels and tumor-to-background contrast. Additional assessments include dosimetry and pathological analysis of lesions when available. The entire participation period includes these imaging sessions and follow-up evaluations lasting about one month after study completion.
CONDITIONS
Brief Title
68Ga-NYM207 PET/CT Imaging in Hepatocellular Carcinoma
Research Team
L
Li Huo
W
Wenjia Zhu
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here